Cytokinetics CYTK Payment-in-kind interest
Payment-in-kind interest at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's payment-in-kind interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's payment-in-kind interest?
- Cytokinetics (CYTK) reported payment-in-kind interest of $8.46M in Q1 2026.
- How has Cytokinetics's payment-in-kind interest changed year-over-year?
- Cytokinetics's payment-in-kind interest increased by 144.9% year-over-year, from $3.45M to $8.46M.
- What is the long-term trend for Cytokinetics's payment-in-kind interest?
- Over 3 years (2021 to 2025), Cytokinetics's payment-in-kind interest has grown at a 47.6% compound annual growth rate (CAGR), from $7.13M to $22.9M.
- What does payment-in-kind interest mean?
- Interest expense added to the loan balance instead of being paid in cash.
- How do you interpret payment-in-kind interest?
- An increase suggests the company is preserving cash but accumulating higher future debt obligations.
- How does payment-in-kind interest compare across companies?
- Common in biotech and growth-stage companies managing liquidity constraints.